P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer

MLA

Hideo Yasugahira, et al. “P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 13, Oct. 2018, p. S984. EBSCOhost, https://doi.org/10.1016/j.jtho.2018.08.1862.

APA

Hideo Yasugahira, Takeshi Morimoto, Toshihiro Shiratori, Yoshiko Ishioka, Hiroshi Tanaka, Koichi Okudera, Yoshinori Hasegawa, Shingo Takanashi, Masamichi Itoga, Hideyuki Nakagawa, Keisuke Baba, Yoshihito Tanaka, Sadatomo Tasaka, & Kageaki Taima. (2018). P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, S984. https://doi.org/10.1016/j.jtho.2018.08.1862

Chicago

Hideo Yasugahira, Takeshi Morimoto, Toshihiro Shiratori, Yoshiko Ishioka, Hiroshi Tanaka, Koichi Okudera, Yoshinori Hasegawa, et al. 2018. “P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology 13 (October): S984. doi:10.1016/j.jtho.2018.08.1862.